The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid ...
THE WOODLANDS, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company has made the strategic decision to eliminate its commercial ...
Our End-of-Phase 2 meeting with FDA was productive and provided Lexicon with the insights needed to design a robust Phase 3 program, with the goal of making the first non-opioid DPNP medicine ...
THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, ...
THE WOODLANDS, Texas, June 23, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) (Nasdaq: LXRX) today announced plans to advance its investigational drug LX9211 into late-stage development ...
“We are implementing a strategic realignment of Lexicon around some truly compelling assets, with a focus on LX9211 for neuropathic pain and other early-stage research and development programs,” said ...
Invus could invest up to $550 million, and Lexicon will provide $60 million to Symphony, created to develop Lexicon’s first three candidates. Lexicon Pharmaceuticals inked a $60-million deal with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results